Halis Akturk, MD
Endocrinology, Diabetes & Metabolism · Aurora, CONPI 1417245143
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Dexcom, Inc. at 36.1% of the total. 2025 is the largest year on record at $41,430, more than ten times the $3,873 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $542.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$39K
- Medtronic$29K
- F. Hoffmann-la Roche AG$14K
- Eli Lilly$7K
- Novo Nordisk AS$5K
- Sanofi$4K
- plus $11K from 9 others
Across 97 payments — averaging $17,104 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$455K
- Senseonics, Incorporated$431K
- Tandem Diabetes Care, Inc.$267K
- Eli Lilly$203K
- Mannkind Corporation$150K
- Abbott$100K
- plus $53K from 2 others
What the payments were for
- Consulting fees$25,05023%
- Speaking & faculty fees$55,39551%
- Grants$570%
- Travel & lodging$20,94619%
- Food & beverage$6,9396%
- Education$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 45 | $39,238 |
| Medtronic(2 entities) | 44 | $28,924 |
| F. Hoffmann-la Roche AG | 8 | $14,115 |
| Eli Lilly | 33 | $6,962 |
| Novo Nordisk AS | 2 | $4,500 |
| Sanofi | 3 | $4,284 |
| Tandem Diabetes Care, Inc. | 22 | $4,163 |
| Mannkind Corporation | 10 | $2,642 |
| Insulet Corporation | 9 | $2,248 |
| Ascensia Diabetes Care US Inc. | 1 | $425 |
| Abbott | 6 | $352 |
| Sanofi-aventis U.S. LLC | 7 | $260 |
| Novo Nordisk | 8 | $238 |
| BETA Bionics, Inc. | 1 | $118 |
| Xeris Pharmaceuticals, Inc. | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$38,010
- MINIMED 780G$22,654
- DEXCOM STELO GLUCOSE BIOSENSOR$11,808
- AFREZZA$2,454
- t-slim insulin pump$2,421
- Omnipod$2,111
- t:slim X2 Insulin Pump with Control-IQ$1,409
- EVERSENSE E3 SENSOR KIT - RETAIL$425
- iLet Bionic Pancreas$353
- DEXCOM G6 TRANSMITTER$247
- Minimed 670G System$134
- iLet Insulin Infusion Kit Inset$118
- iLet Insulin Infusion Kit Contact Detach$118
How this compares
$108,547 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $43,358 |
| OzempicSemaglutide | 31 | $29,866 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $20,238 |
| HumalogInsulin Lispro | 41 | $12,493 |
| Humalog Kwikpen U-100Insulin Lispro | 54 | $10,818 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $9,554 |
| JardianceEmpagliflozin | 14 | $8,720 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $4,699 |
| Novolog FlexpenInsulin Aspart | 14 | $3,791 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $2,566 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 13 | $1,523 |
| SynthroidLevothyroxine Sodium | 12 | $692 |
| Atorvastatin Calcium | 56 | $597 |
| Levothyroxine Sodium | 47 | $502 |
| Losartan Potassium | 29 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $238 | $29,86631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Aurora
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Robert EckelAurora$66K
- Marc Andre CornierAurora$62K
- Jane ReuschAurora$59K
- James FalkoAurora$45K
- Aaron MichelsAurora$37K
- Margaret WiermanAurora$36K
- Peter GottliebAurora$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.